Intimate partner violence (IPV) is a complex public health crisis with far-reaching consequences for Veterans and their families. The healthcare system plays an integral role in the detection and treatment of IPV through implementation of IPV screening and provision of resources in response to IPV disclosures. The National IPV Assistance Program (IPVAP) is in the process of expanding the screening directive from women and at-risk Veterans to a national rollout and updated directive indicating that Veterans of all genders are to be screened annually for IPV using the Relationship Health and Safety (RHS 3.0) screener. Evaluating the implementation and impact of this updated national screening rollout is a critical priority for IPVAP. Prior HSR&D funded research has focused on identifying barriers and facilitators of implementing IPV screening among women of reproductive age in primary care settings. However, little is known about the implementation or clinical impact of screening patients of all genders and ages for IPV. The proposed study builds on past findings by evaluating the national rollout expanding IPV screening to all Veterans. IPVAP’s updated directive requires foundational screening implementation and outcome data among non-women Veterans and the development of data tracking and systems. Additionally, a critical missing piece needed to inform scale-up of IPV screening to all Veterans is data on the impact of IPV screening through identification of patient outcomes following IPV disclosures. A robust partnered evaluation of the expanded IPV screening national rollout will extend prior work and assist IPVAP in determining implementation and clinical impact outcomes. We plan to simultaneously evaluate the rollout of IPVAP’s expanded national IPV screening directive now targeting all patients while also examining the impact of this new initiative to provide innovative and critically needed data on the impact of screening non-women patients to the Program Office. As a result, we will develop the tools and systems essential for IPVAP to monitor screening implementation across clinical settings and identify Veteran-focused outcomes related to IPV screening and positive disclosures, and best practices for scale-up and maintenance of IPV screening among all Veterans. The specific aims of this PEI are to (1) Evaluate implementation of the expanded RHS 3.0 screening and response national by (a) assessing IPV screening implementation outcomes across RE-AIM domains (reach, effectiveness, adoption, implementation, and maintenance); (b) examining potential differences in outcomes by patient characteristics (e.g., gender, age, race, ethnicity, sexual orientation, marital status); and (c) identifying clinical settings and provider types most and least likely to screen for IPV and yield positive IPV disclosures during screening. (2) Identify impact of IPV screening on patients as well as potential gender differences in impact by (a) examining service uti...